These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22920638)

  • 1. The role of immunological assessment in patients with acute kidney injury and possible myeloma.
    Lachmann HJ; Wassef NL
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):287-90. PubMed ID: 22920638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management options for cast nephropathy in multiple myeloma.
    Cockwell P; Hutchison CA
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
    Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S
    J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute kidney injury with cast nephropathy.
    Walther C; Podoll AS; Finkel KW
    Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.
    Heaney JLJ; Campbell JP; Yadav P; Griffin AE; Shemar M; Pinney JH; Drayson MT
    BMC Nephrol; 2017 Jul; 18(1):247. PubMed ID: 28728609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Cockwell P; Cook M
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pathogenesis of acute kidney impairment in patients with multiple myeloma.
    Batuman V
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):282-6. PubMed ID: 22920637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
    Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
    Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum free light chains for monitoring multiple myeloma.
    Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
    Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
    Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
    Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
    Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracorporeal treatment of cast nephropathy.
    Gakhar B; Kobrin S; Berns JS
    Semin Dial; 2011; 24(1):9-11. PubMed ID: 21324000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
    Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
    Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR
    J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biochemical and immunological findings of multiple myeloma].
    Asaoku H
    Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma light chain cast nephropathy, a review.
    Sathick IJ; Drosou ME; Leung N
    J Nephrol; 2019 Apr; 32(2):189-198. PubMed ID: 29730782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Determination of light chains in serum].
    Hansen CT; Nielsen L; Münster AM; Abildgaard N
    Ugeskr Laeger; 2010 Aug; 172(34):2302-5. PubMed ID: 20727297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.